丹诺医药冲刺IPO，核心产品临近上市

Core Viewpoint - Danuo Pharmaceutical (Suzhou) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Agricultural Bank of China International as joint sponsors [1] Group 1: Company Overview - Founded in 2013, Danuo Pharmaceutical is a biotech company focused on discovering, developing, and commercializing innovative drug products to address unmet clinical needs in bacterial infections and related diseases [5] - The company has seven innovative projects, with two core products: TNP-2198 (Rifoterinazole) and TNP-2092 (Rifofloxacin injection) [5] Group 2: Product Development - TNP-2198 is the first and only new molecular entity candidate for treating Helicobacter pylori infection since its discovery in 1982, with a New Drug Application (NDA) expected to be approved by the end of 2026 [5][6] - TNP-2092 is a candidate drug targeting three types of bacterial infections related to implanted devices and has received clinical trial approval from both the National Medical Products Administration (NMPA) and the FDA [5] Group 3: Financial Performance - Danuo Pharmaceutical reported cumulative losses of 453 million yuan over the past two years, with no revenue generated in 2023, 2024, and the first three quarters of 2025, and net losses of 192 million yuan, 146 million yuan, and 115 million yuan respectively [2][6] - Research and development expenditures for the same periods were 108 million yuan, 69.84 million yuan, and 46.39 million yuan [6] Group 4: Valuation and Shareholding - The latest valuation of Danuo Pharmaceutical is approximately 2.013 billion yuan [2][12] - Cumbre entities are the largest shareholders, holding about 18.82% of the voting rights, while the founder and CEO, Ma Zhenkun, controls approximately 13.61% of the voting rights [8]